Atlas Trials

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Clinical trial NCT04213261 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04213261
Sponsor
Castle Creek Biosciences, LLC.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Recessive Dystrophic Epidermolysis Bullosa
Start date
2020-06-09
Primary completion
2023-01-17
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.